 |
0 Diseases |  |
9 Trials |
|
9 Trials |  |
96 News |  |
| «123» |
- ONO-5788 / Ono Pharma
Enrollment change, Trial termination: A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers (clinicaltrials.gov) - Jun 5, 2019
P1, N=76, Terminated, Sponsor: Ono Pharmaceutical Co. Ltd
N=136 --> 76 | Recruiting --> Terminated; The study met a pre-defined protocol study stopping criteria
- | Glypressin (terlipressin) / Ferring
Enrollment open: Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage (clinicaltrials.gov) - Mar 25, 2019
P=N/A, N=2000, Recruiting, Sponsor: General Hospital of Shenyang Military Region
N=136 --> 76 | Recruiting --> Terminated; The study met a pre-defined protocol study stopping criteria Not yet recruiting --> Recruiting
- | Glypressin (terlipressin) / Ferring
New trial: Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage (clinicaltrials.gov) - Feb 19, 2019
P, N=2000, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
- || ONO-5788 / Ono Pharma
Trial completion date, Trial primary completion date: A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers (clinicaltrials.gov) - Jan 7, 2019
P1, N=136, Recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
Not yet recruiting --> Recruiting Trial completion date: Jan 2019 --> Apr 2019 | Trial primary completion date: Jan 2019 --> Apr 2019
- | octreotide acetate solution for injection / Generic mfg.
New trial: SANDOSTATINE: Evaluation of Impact of Sandostatin (clinicaltrials.gov) - Jan 3, 2019
P=N/A, N=4, Terminated, Sponsor: Institut Cancerologie de l'Ouest
- | octreotide acetate solution for injection / Generic mfg.
Trial completion, Enrollment change, Surgery: Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer (clinicaltrials.gov) - Nov 8, 2018
P=N/A, N=20, Completed, Sponsor: St. James's Hospital, Ireland
Trial completion date: Jan 2019 --> Apr 2019 | Trial primary completion date: Jan 2019 --> Apr 2019 Enrolling by invitation --> Completed | N=80 --> 20
- | octreotide acetate solution for injection / Generic mfg.
Trial completion, Enrollment change, Surgery: The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery (clinicaltrials.gov) - Nov 7, 2018
P=N/A, N=40, Completed, Sponsor: St. James's Hospital, Ireland
Enrolling by invitation --> Completed | N=80 --> 20 Enrolling by invitation --> Completed | N=80 --> 40
- | octreotide acetate solution for injection / Generic mfg.
Enrollment open: A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors (clinicaltrials.gov) - Oct 5, 2018
P1, N=30, Recruiting, Sponsor: Massachusetts General Hospital
Enrolling by invitation --> Completed | N=80 --> 40 Not yet recruiting --> Recruiting
- ||| ONO-5788 / Ono Pharma
New P1 trial: A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers (clinicaltrials.gov) - Jun 27, 2018
P1, N=136, Recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- | octreotide acetate solution for injection / Generic mfg.
Enrollment open, HEOR: The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research (clinicaltrials.gov) - Jun 3, 2018
P=N/A, N=1965, Recruiting, Sponsor: Ginkgo Leaf Center for Rare Disorders
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | octreotide acetate solution for injection / Generic mfg.
Enrollment closed, Trial primary completion date: PANasta: Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy (clinicaltrials.gov) - Nov 1, 2017
P3, N=506, Active, not recruiting, Sponsor: University of Liverpool
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jul 2018
- | Comtan (entacapone) / Novartis, Orion Corp
Trial primary completion date: Treatment of Orthostatic Intolerance (clinicaltrials.gov) - Sep 14, 2017
P1/2, N=150, Active, not recruiting, Sponsor: Satish R. Raj
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jul 2018 Trial primary completion date: Jan 2018 --> Dec 2021
- | octreotide acetate solution for injection / Generic mfg.
Phase classification, Trial initiation date: A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors (clinicaltrials.gov) - Aug 29, 2017
P1, N=30, Not yet recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jan 2018 --> Dec 2021 Phase classification: P=N/A --> P1 | Initiation date: Feb 2017 --> Oct 2017
- | octreotide acetate solution for injection / Generic mfg.
Trial initiation date, Trial primary completion date: Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=104, Completed, Sponsor: Mansoura University
Phase classification: P=N/A --> P1 | Initiation date: Feb 2017 --> Oct 2017 Initiation date: May 2015 --> May 2014 | Trial primary completion date: Jan 2017 --> Apr 2017
- | octreotide acetate solution for injection / Generic mfg.
New trial, HEOR: The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research (clinicaltrials.gov) - May 17, 2017
P=N/A, N=1965, Not yet recruiting, Sponsor: Ginkgo Leaf Center for Rare Disorders
- | octreotide intranasal (DP1038) / Dauntless Pharma
Trial completion: Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers (clinicaltrials.gov) - May 12, 2017
P1, N=32, Completed, Sponsor: Dauntless Pharmaceuticals
Initiation date: May 2015 --> May 2014 | Trial primary completion date: Jan 2017 --> Apr 2017 Recruiting --> Completed
- | octreotide acetate solution for injection / Generic mfg.
Trial completion, Trial primary completion date: Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=100, Completed, Sponsor: Mansoura University
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2017
- | octreotide acetate solution for injection / Generic mfg.
Trial completion: Octreotide Efficacy and Safety in First-line Acromegalic Patients (clinicaltrials.gov) - Feb 24, 2017
P4, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2017 Suspended --> Completed
- | octreotide acetate solution for injection / Generic mfg.
New trial: A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors (clinicaltrials.gov) - Feb 19, 2017
P=N/A, N=30, Not yet recruiting, Sponsor: Massachusetts General Hospital
- octreotide intranasal (DP1038) / Dauntless Pharma
New P1 trial: Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers (clinicaltrials.gov) - Jan 26, 2017
P1, N=32, Recruiting, Sponsor: Dauntless Pharmaceuticals
- Ergonex (ergotamine/caffeine) / AC Farma
Phase classification, Enrollment change: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jan 18, 2017
P1, N=389, Completed, Sponsor: Vanderbilt University
Suspended --> Completed Phase classification: P3 --> P1 | N=80 --> 389
- | Ergonex (ergotamine/caffeine) / AC Farma
Trial completion, Enrollment change, Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jan 17, 2017
P3, N=80, Completed, Sponsor: Vanderbilt University
Phase classification: P3 --> P1 | N=80 --> 389 Recruiting --> Completed | N=500 --> 80 | Trial primary completion date: Apr 2017 --> Jan 2017
- octreotide acetate solution for injection / Generic mfg.
Trial completion, Enrollment change: GLEE: Effects of Glucagon Administration on Energy Expenditure (clinicaltrials.gov) - Jan 13, 2017
P1, N=6, Completed, Sponsor: Translational Research Institute for Metabolism and Diabetes, Florida
Recruiting --> Completed | N=500 --> 80 | Trial primary completion date: Apr 2017 --> Jan 2017 Active, not recruiting --> Completed | N=20 --> 6
- octreotide acetate solution for injection / Generic mfg., fludarabine IV / Generic mfg.
Trial primary completion date: Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 15, 2016
P2, N=34, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=20 --> 6 Trial primary completion date: Jun 2015 --> Jul 2000
- |||| Signifor (pasireotide) / Recordati
Trial completion: Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients (clinicaltrials.gov) - Nov 6, 2016
P2, N=62, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2015 --> Jul 2000 Active, not recruiting --> Completed
- octreotide acetate solution for injection / Generic mfg.
Trial primary completion date, Surgery: Investigation of the Effects of Obesity Surgery on Appetitive Behaviour (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=30, Recruiting, Sponsor: University College Dublin
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Jun 2018
- | octreotide subcutaneous depot (CAM2029) / Camurus
Trial completion, Enrollment change: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Oct 11, 2016
P2, N=12, Completed, Sponsor: Camurus AB
Trial primary completion date: Feb 2016 --> Jun 2018 Active, not recruiting --> Completed | N=24 --> 12
- | Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Trial completion: Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects (clinicaltrials.gov) - Sep 7, 2016
P1, N=24, Completed, Sponsor: Lexicon Pharmaceuticals
Active, not recruiting --> Completed | N=24 --> 12 Active, not recruiting --> Completed
- | cixutumumab (IMC A12) / Eli Lilly
Trial completion, Combination therapy, Metastases: A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer (clinicaltrials.gov) - Aug 16, 2016
P2, N=43, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| octreotide acetate solution for injection / Generic mfg.
New P2 trial: Evaluation of the impact of a Sandostatin injection before axillary node dissection on lymphorrhea in patients operated for breast cancer Evaluation de l'impact d'une injection de Sandostatine avant un curage axillaire sur les lymphoc (EUDRACT) - Jun 10, 2016
P2, N=67, Ongoing, Sponsor: Institut de Canc
- Ergonex (ergotamine/caffeine) / AC Farma
Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Apr 28, 2016
P3, N=500, Recruiting, Sponsor: Vanderbilt University
Active, not recruiting --> Completed Trial primary completion date: Apr 2016 --> Apr 2017
- octreotide subcutaneous depot (CAM2029) / Camurus
Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Mar 15, 2016
P2, N=24, Active, not recruiting, Sponsor: Camurus AB
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Feb 2016 --> May 2016
- octreotide acetate solution for injection / Generic mfg.
Enrollment change, Trial primary completion date, Surgery: Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer (clinicaltrials.gov) - Feb 2, 2016
P=N/A, N=80, Enrolling by invitation, Sponsor: St. James's Hospital, Ireland
Trial primary completion date: Feb 2016 --> May 2016 N=35 --> 80 | Trial primary completion date: Dec 2015 --> Dec 2017
- octreotide acetate solution for injection / Generic mfg.
Enrollment change, Trial primary completion date, Surgery: The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery (clinicaltrials.gov) - Feb 2, 2016
P=N/A, N=80, Enrolling by invitation, Sponsor: St. James's Hospital, Ireland
N=35 --> 80 | Trial primary completion date: Dec 2015 --> Dec 2017 N=36 --> 80 | Trial primary completion date: Mar 2016 --> Mar 2018
- | octreotide subcutaneous depot (CAM2029) / Camurus
Enrollment closed, Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Nov 27, 2015
P2, N=24, Active, not recruiting, Sponsor: Camurus AB
N=36 --> 80 | Trial primary completion date: Mar 2016 --> Mar 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Feb 2016
- octreotide acetate solution for injection / Generic mfg.
Enrollment closed: GLEE: Effects of Glucagon Administration on Energy Expenditure (clinicaltrials.gov) - Oct 28, 2015
P1, N=20, Active, not recruiting, Sponsor: Translational Research Institute for Metabolism and Diabetes, Florida
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- octreotide acetate solution for injection / Generic mfg., fludarabine IV / Generic mfg.
Trial completion: Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 15, 2015
P2, N=34, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| octreotide acetate solution for injection / Generic mfg.
New trial: Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Mansoura University
- octreotide acetate solution for injection / Generic mfg.
Trial primary completion date, Surgery: Investigation of the Effects of Obesity Surgery on Appetitive Behaviour (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=30, Recruiting, Sponsor: University College Dublin
Active, not recruiting --> Completed Trial primary completion date: Feb 2014 --> Feb 2016
- octreotide subcutaneous depot (CAM2029) / Camurus
Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Jun 11, 2015
P2, N=24, Recruiting, Sponsor: Camurus AB
Trial primary completion date: Feb 2014 --> Feb 2016 Trial primary completion date: Apr 2015 --> Oct 2015
- Ergonex (ergotamine/caffeine) / AC Farma
Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jun 11, 2015
P3, N=500, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Apr 2015 --> Oct 2015 Trial primary completion date: May 2015 --> Apr 2016
- |||||||||| octreotide acetate solution for injection / Generic mfg.
New P3 trial: PANasta: Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy (clinicaltrials.gov) - May 29, 2015
P3, N=506, Recruiting, Sponsor: University of Liverpool
- octreotide acetate solution for injection / Generic mfg.
Surgery: Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=35, Enrolling by invitation, Sponsor: St. James's Hospital, Ireland
- octreotide acetate solution for injection / Generic mfg.
Surgery: The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=36, Enrolling by invitation, Sponsor: St. James's Hospital, Ireland
- | octreotide subcutaneous depot (CAM2029) / Camurus
Enrollment open: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Jan 26, 2015
P2, N=24, Recruiting, Sponsor: Camurus AB
Trial primary completion date: May 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- Comtan (entacapone) / Novartis, Orion Corp
Enrollment closed, Trial primary completion date: Treatment of Orthostatic Intolerance (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=150, Active, not recruiting, Sponsor: Satish R. Raj
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jan 2018
- | octreotide subcutaneous depot (CAM2029) / Camurus
New P2 trial: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Nov 24, 2014
P2, N=24, Not yet recruiting, Sponsor: Camurus AB
- octreotide acetate solution for injection / Generic mfg.
Enrollment open: GLEE: Effects of Glucagon Administration on Energy Expenditure (clinicaltrials.gov) - Oct 30, 2014
P1, N=20, Recruiting, Sponsor: Translational Research Institute for Metabolism and Diabetes, Florida
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jan 2018 Not yet recruiting --> Recruiting
- octreotide acetate solution for injection / Generic mfg.
New P1 trial: GLEE: Effects of Glucagon Administration on Energy Expenditure (clinicaltrials.gov) - Sep 11, 2014
P1, N=20, Not yet recruiting, Sponsor: Translational Research Institute for Metabolism and Diabetes, Florida
- Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Enrollment closed: Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects (clinicaltrials.gov) - Sep 8, 2014
P1, N=24, Active, not recruiting, Sponsor: Lexicon Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting